vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and MARINE PRODUCTS CORP (MPX). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $64.6M, roughly 1.3× MARINE PRODUCTS CORP). On growth, MARINE PRODUCTS CORP posted the faster year-over-year revenue change (35.0% vs 17.7%). MARINE PRODUCTS CORP produced more free cash flow last quarter ($4.1M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -3.5%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
West Marine is an American company based in Fort Lauderdale, Florida, which operates a chain of boating supply and fishing retail stores. The company has 247 retail stores in North America. West Marine also runs Blue Future a non profit organization. West Marine's flagship store is in Fort Lauderdale. Opened on November 11, 2011, the store is the company's largest at over 50,000 square feet.
IOVA vs MPX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $64.6M |
| Net Profit | — | $2.4M |
| Gross Margin | 67.4% | 19.6% |
| Operating Margin | -84.7% | 5.8% |
| Net Margin | — | 3.7% |
| Revenue YoY | 17.7% | 35.0% |
| Net Profit YoY | — | -44.6% |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $64.6M | ||
| Q3 25 | $67.5M | $53.1M | ||
| Q2 25 | $60.0M | $67.7M | ||
| Q1 25 | $49.3M | $59.0M | ||
| Q4 24 | $73.7M | $47.8M | ||
| Q3 24 | $58.6M | $49.9M | ||
| Q2 24 | $31.1M | $69.5M | ||
| Q1 24 | $715.0K | $69.3M |
| Q4 25 | — | $2.4M | ||
| Q3 25 | $-91.3M | $2.6M | ||
| Q2 25 | $-111.7M | $4.2M | ||
| Q1 25 | $-116.2M | $2.2M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | $-83.5M | $3.4M | ||
| Q2 24 | $-97.1M | $5.6M | ||
| Q1 24 | $-113.0M | $4.6M |
| Q4 25 | 67.4% | 19.6% | ||
| Q3 25 | 43.0% | 19.2% | ||
| Q2 25 | 5.5% | 19.1% | ||
| Q1 25 | -0.8% | 18.6% | ||
| Q4 24 | 68.7% | 19.2% | ||
| Q3 24 | 46.2% | 18.4% | ||
| Q2 24 | -0.8% | 18.9% | ||
| Q1 24 | — | 20.2% |
| Q4 25 | -84.7% | 5.8% | ||
| Q3 25 | -140.7% | 5.4% | ||
| Q2 25 | -189.8% | 7.1% | ||
| Q1 25 | -245.8% | 4.4% | ||
| Q4 24 | -117.5% | 7.7% | ||
| Q3 24 | -152.1% | 7.2% | ||
| Q2 24 | -327.6% | 8.3% | ||
| Q1 24 | -16464.6% | 7.6% |
| Q4 25 | — | 3.7% | ||
| Q3 25 | -135.3% | 5.0% | ||
| Q2 25 | -186.2% | 6.1% | ||
| Q1 25 | -235.5% | 3.7% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | -142.7% | 6.8% | ||
| Q2 24 | -312.2% | 8.0% | ||
| Q1 24 | -15800.8% | 6.6% |
| Q4 25 | — | $0.07 | ||
| Q3 25 | — | $0.07 | ||
| Q2 25 | $-0.33 | $0.12 | ||
| Q1 25 | $-0.36 | $0.06 | ||
| Q4 24 | $-0.24 | $0.13 | ||
| Q3 24 | $-0.28 | $0.10 | ||
| Q2 24 | $-0.34 | $0.14 | ||
| Q1 24 | $-0.42 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $125.0M |
| Total Assets | $913.2M | $147.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | — | ||
| Q3 25 | $300.8M | — | ||
| Q2 25 | $301.2M | — | ||
| Q1 25 | $359.7M | — | ||
| Q4 24 | $323.8M | — | ||
| Q3 24 | $397.5M | — | ||
| Q2 24 | $412.5M | — | ||
| Q1 24 | $356.2M | — |
| Q4 25 | $698.6M | $125.0M | ||
| Q3 25 | $702.3M | $126.3M | ||
| Q2 25 | $698.5M | $127.2M | ||
| Q1 25 | $767.9M | $126.4M | ||
| Q4 24 | $710.4M | $129.0M | ||
| Q3 24 | $773.5M | $128.8M | ||
| Q2 24 | $768.5M | $129.3M | ||
| Q1 24 | $680.0M | $151.4M |
| Q4 25 | $913.2M | $147.2M | ||
| Q3 25 | $904.9M | $179.5M | ||
| Q2 25 | $907.4M | $173.2M | ||
| Q1 25 | $966.7M | $182.9M | ||
| Q4 24 | $910.4M | $171.2M | ||
| Q3 24 | $991.1M | $176.3M | ||
| Q2 24 | $964.3M | $175.7M | ||
| Q1 24 | $869.8M | $204.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $4.7M |
| Free Cash FlowOCF − Capex | $-61.9M | $4.1M |
| FCF MarginFCF / Revenue | -71.3% | 6.4% |
| Capex IntensityCapex / Revenue | 10.7% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 2.00× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $14.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $4.7M | ||
| Q3 25 | $-78.7M | $2.6M | ||
| Q2 25 | $-67.4M | $-1.6M | ||
| Q1 25 | $-103.7M | $10.8M | ||
| Q4 24 | $-73.3M | $4.6M | ||
| Q3 24 | $-59.0M | $5.1M | ||
| Q2 24 | $-98.4M | $3.8M | ||
| Q1 24 | $-122.3M | $15.9M |
| Q4 25 | $-61.9M | $4.1M | ||
| Q3 25 | $-89.5M | $2.1M | ||
| Q2 25 | $-74.9M | $-2.0M | ||
| Q1 25 | $-109.9M | $10.7M | ||
| Q4 24 | $-77.5M | $3.6M | ||
| Q3 24 | $-61.3M | $3.2M | ||
| Q2 24 | $-98.9M | $3.0M | ||
| Q1 24 | $-126.5M | $15.0M |
| Q4 25 | -71.3% | 6.4% | ||
| Q3 25 | -132.7% | 4.0% | ||
| Q2 25 | -124.9% | -3.0% | ||
| Q1 25 | -222.8% | 18.1% | ||
| Q4 24 | -105.1% | 7.6% | ||
| Q3 24 | -104.6% | 6.5% | ||
| Q2 24 | -317.9% | 4.4% | ||
| Q1 24 | -17685.3% | 21.7% |
| Q4 25 | 10.7% | 0.9% | ||
| Q3 25 | 16.1% | 0.8% | ||
| Q2 25 | 12.4% | 0.6% | ||
| Q1 25 | 12.6% | 0.2% | ||
| Q4 24 | 5.7% | 2.1% | ||
| Q3 24 | 3.9% | 3.8% | ||
| Q2 24 | 1.4% | 1.1% | ||
| Q1 24 | 583.4% | 1.3% |
| Q4 25 | — | 2.00× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | -0.39× | ||
| Q1 25 | — | 4.88× | ||
| Q4 24 | — | 1.09× | ||
| Q3 24 | — | 1.51× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | — | 3.46× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
MPX
| Boats And Accessories | $63.4M | 98% |
| Parts | $1.1M | 2% |
